GIMEMA LAL2116, D-ALBA, Updated Results and Prognostic Impact of IKZF1 in Ph+ ALL
Robin Foà, MD, leads a discussion on the primary takeaways from the GIMEMA LAL2116, D-ALBA trial, particularly the prognostic impact of the IKZF1-plus genotype and the Ikaros mutation.
Read More